<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DEPOCYT- cytarabine injection, lipid complex </strong><br>Sigma-Tau Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use DEPOCYT<span class="Sup">®</span> safely and effectively.  See full prescribing information for DEPOCYT. 
			<br><br>DEPOCYT (cytarabine liposome injection)<br>For Intrathecal Use Only<br> Initial U.S. Approval: 1999
		</span></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: CHEMICAL <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">ARACHNOIDITIS</span> ADVERSE REACTIONS</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Bold Highlighta">Chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span>, a syndrome manifested primarily by <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, was a common adverse event in all clinical studies.  If left untreated, chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span> may be fatal.  Patients receiving DepoCyt should be treated concurrently with dexamethasone to mitigate the symptoms of chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span>.  (<a href="#MN051">5.1</a>, <a href="#MN052">5.2</a>)) </p>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: CHEMICAL <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">ARACHNOIDITIS</span> ADVERSE REACTIONS</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Bold Highlighta">Chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span>, a syndrome manifested primarily by <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, was a common adverse event in all clinical studies.  If left untreated, chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span> may be fatal.  Patients receiving DepoCyt should be treated concurrently with dexamethasone to mitigate the symptoms of chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span>.  (<a href="#MN051">5.1</a>, <a href="#MN052">5.2</a>)) </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">DepoCyt is indicated for the intrathecal treatment of lymphomatous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. (<a href="#MN010">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">DepoCyt is for intrathecal use only.  (<a href="#MN023">2.3</a>) </p>
<ul>
<li>
<span class="Underline">Induction therapy</span>:  DepoCyt, 50 mg, administer intrathecally (intraventricular or lumbar puncture) every 14 days for 2 doses (weeks 1 and 3) (<a href="#MN024">2.4</a>)</li>
<li>
<span class="Underline">Consolidation therapy</span>:  DepoCyt, 50 mg, administer intrathecally (intraventricular or lumbar puncture) every 14 days for 3 doses (weeks 5, 7 and 9) followed by 1 additional dose at week 13  (<a href="#MN024">2.4</a>)</li>
<li>
<span class="Underline">Maintenance</span>:  DepoCyt, 50 mg, administer intrathecally (intraventricular or lumbar puncture) every 28 days for 4 doses (weeks 17, 21, 25 and 29)  (<a href="#MN024">2.4</a>)</li>
</ul>
<p class="Highlighta">Initiate dexamethasone 4 mg twice a day either by mouth or intravenously for 5 days beginning on the day of DepoCyt injection.  If drug related <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> develops, reduce DepoCyt to 25 mg.  If <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> persists, discontinue DepoCyt.  (<a href="#MN024">2.4</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Single-dose vial containing 50 mg/5 mL (10 mg/mL) of cytarabine liposome injection (<a href="#MN030">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>Hypersensitive to cytarabine or any component of the formulation with active meningeal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (<a href="#MN040">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span>: <span class="product-label-link" type="condition" conceptid="135526" conceptname="Spinal cord disease">Myelopathy</span> and other neurologic toxicity may occur. Reduce the dose or discontinue DepoCyt.  (<a href="#MN052">5.2</a>)</li>
<li>Embryo-fetal Toxicity: May cause fetal harm.  Advise women of potential harm to a fetus and to avoid pregnancy if receiving DepoCyt. (<a href="#MN054">5.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence ≥20%) are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span> , <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> , <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>. (<a href="#MN061">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sigma-Tau Pharmaceuticals, Inc. at 1-888-393-4584 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: CHEMICAL <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">ARACHNOIDITIS</span></a></h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Preparation and Administration Precautions</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Preparation and Administration</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosing Precautions</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dosing Regimen</a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">Arachnoiditis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Transient Elevations in CSF Protein and CSF White Blood Cells</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Embryo-fetal Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Most Frequently Reported Reactions</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy Category D</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.6 Hepatic and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3  Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14  CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Study 1 – <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">Solid Tumors</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span>, or <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span> </a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Study 2 – <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></a></h2>
<h1><a href="#section-14" class="toc">15  REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="MN000"></a><a name="section-1"></a><p></p>
<h1>WARNING: CHEMICAL <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">ARACHNOIDITIS</span></h1>
<p class="Bold First">Chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span>, a syndrome manifested primarily by <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, was a common adverse event in all clinical studies.  If left untreated, chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span> may be fatal.  Patients receiving DepoCyt should be treated concurrently with dexamethasone to mitigate the symptoms of chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span>.  [<span class="Italics">see Warnings and Precautions (<a href="#MN051">5.1</a>, <a href="#MN052">5.2</a>)</span>]</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="MN010"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<p class="First">DepoCyt<span class="Sup">®</span> (cytarabine liposome injection) is indicated for the intrathecal treatment of lymphomatous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="MN020"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="MN021"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Preparation and Administration Precautions</h2>
<p class="First">DepoCyt is a cytotoxic anticancer drug and, as with other potentially toxic compounds, caution should be used in handling DepoCyt.  The use of gloves is recommended.  If DepoCyt suspension contacts the skin, wash immediately with soap and water.  If it contacts mucous membranes, flush thoroughly with water.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="MN022"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Preparation and Administration</h2>
<p class="First">No further reconstitution or dilution is required.  DepoCyt particles have a tendency to settle with time.  Vials of DepoCyt should be allowed to warm to room temperature and gently <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or inverted to re-suspend the particles immediately prior to withdrawal from the vial.  Avoid aggressive <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>.  </p>
<p>DepoCyt should be withdrawn from the vial immediately before administration. DepoCyt is a single dose vial and does not contain any preservative. DepoCyt should be used within 4 hours of withdrawal from the vial.  Unused portions of each vial should be discarded properly [<span class="Italics">see How Supplied/ Storage and Handling (<a href="#MN160">16</a>)</span>].  Do not save any unused portions for later administration.  Do not mix DepoCyt with any other medications.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="MN023"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dosing Precautions</h2>
<p class="First">In-line filters must not be used when administering DepoCyt. DepoCyt is administered directly into the cerebrospinal fluid (CSF) via an intraventricular reservoir or by direct injection into the lumbar sac.  DepoCyt should be injected slowly over a period of 1-5 minutes.  Following drug administration by lumbar puncture, the patient should be instructed to lie flat for 1 hour.  Patients should be observed by the physician for immediate toxic reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="MN024"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dosing Regimen</h2>
<p class="First">For the treatment of lymphomatous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, DepoCyt 50 mg (one vial of DepoCyt) is recommended to be given according to the following schedule:</p>
<table cellpadding="6" class="Noautorules" width="630"><tbody class="Headless">
<tr>
<td class="Botrule Italics Lrule Rrule Toprule" align="left" valign="top">Induction therapy</td>
<td class="Botrule Lrule Rrule Toprule" align="left">DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar<br> puncture) every 14 days for 2 doses (weeks 1 and 3).</td>
</tr>
<tr>
<td class="Botrule Italics Lrule Rrule Toprule" align="left" valign="top">Consolidation therapy</td>
<td class="Botrule Lrule Rrule Toprule" align="left">DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar <br>puncture) every 14 days for 3 doses (weeks 5, 7 and 9) followed by 1<br> additional dose at week 13.</td>
</tr>
<tr>
<td class="Botrule Italics Lrule Rrule Toprule" align="left" valign="top">Maintenance</td>
<td class="Botrule Lrule Rrule Toprule" align="left">DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar <br>puncture) every 28 days for 4 doses (weeks 17, 21, 25 and 29).</td>
</tr>
</tbody></table>
<p>Patients should be started on dexamethasone 4 mg twice a day either by mouth or intravenously for 5 days beginning on the day of DepoCyt injection.</p>
<p>If drug related <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> develops, the dose should be reduced to 25 mg.  If it persists, treatment with DepoCyt should be discontinued.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="MN030"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Ready-to-use, single dose vial containing 50 mg/5 mL (10 mg/mL) of cytarabine liposome injection.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="MN040"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First">DepoCyt<span class="Sup">®</span> (cytarabine liposome injection) is contraindicated in patients who are hypersensitive to cytarabine or any component of the formulation, and in patients with active meningeal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="MN050"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="MN051"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">Arachnoiditis</span></h2>
<p class="First">Chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span>, a syndrome manifested primarily by <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, has been a common adverse event in all studies.  If chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span> is suspected, exclude other inflammatory, infectious, or neoplastic conditions.   If left untreated, chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span> may be fatal.  The incidence and severity of chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span> can be reduced by coadministration of dexamethasone.  Patients receiving DepoCyt should be treated concurrently with dexamethasone to mitigate the symptoms of chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span> [<span class="Italics">see Dosage and Administration (<a href="#MN020">2</a>)</span>].</p>
<p>Toxic effects may be related to a single dose or to cumulative administration.  Because toxic effects can occur at any time during therapy (although they are most likely to occur within 5 days of drug administration), patients receiving intrathecal therapy with DepoCyt should be monitored continuously for the development of <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>.  If patients develop <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>, reduce subsequent doses of DepoCyt. If <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> persists, discontinue DepoCyt [<span class="Italics">see Warnings and Precautions (<a href="#MN053">5.3</a>)</span>]</p>
<p><span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">Hydrocephalus</span> has also been reported, possibly precipitated by <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span>. </p>
<p><span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">Arachnoiditis</span> is an expected and well-documented side effect of both <span class="product-label-link" type="condition" conceptid="4042194" conceptname="Malignant meningitis">neoplastic meningitis</span> and of intrathecal chemotherapy.  The incidence of severe and life-threatening <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span> in patients receiving DepoCyt was 19% (48/257) in all patients and 30% (10/33) in patients with lymphomatous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>.  In the early dose-finding study, chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span> was observed in 100% of cycles without dexamethasone prophylaxis.  When concurrent dexamethasone was administered, chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span> was observed in 33% of cycles.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="MN052"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span></h2>
<p class="First">Intrathecal administration of cytarabine may cause <span class="product-label-link" type="condition" conceptid="135526" conceptname="Spinal cord disease">myelopathy</span> and other neurologic toxicity and can rarely lead to a permanent neurologic deficit.  Administration of intrathecal cytarabine in combination with other chemotherapeutic agents or with cranial/spinal irradiation may increase this risk of <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>.</p>
<p>Blockage to CSF flow may result in increased free cytarabine concentrations in the CSF and an increased risk of <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>.  Therefore, as with any intrathecal cytotoxic therapy, consideration should be given to the need for assessment of CSF flow before treatment is started.</p>
<p>Following intrathecal administration of DepoCyt, central nervous system toxicity, including persistent extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="374022" conceptname="Hemiplegia">hemiplegia</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> including <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> which may be total and permanent, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span> and cranial nerve palsies have been reported.  Symptoms and signs of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, such as <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and impaired bowel and bladder control have also been observed.  In some cases, a combination of neurological signs and symptoms has been reported as <span class="product-label-link" type="condition" conceptid="4102342" conceptname="Cauda equina syndrome">Cauda Equina Syndrome</span>.</p>
<p>If patients develop <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>, reduce subsequent doses of DepoCyt or discontinue DepoCyt <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> are expected in early signs of <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="MN053"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Transient Elevations in CSF Protein and CSF White Blood Cells</h2>
<p class="First">Transient elevations in CSF protein and white blood cell counts have been observed in patients following DepoCyt administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="MN054"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Embryo-fetal Toxicity</h2>
<p class="First">Cytarabine, the active component of DepoCyt, can cause fetal harm if a pregnant woman is exposed to the drug systemically.  The systemic exposure of cytarabine following intrathecal administration of DepoCyt is negligible. Cytarabine was teratogenic in mice and rats.  Cytarabine was embryotoxic in mice when administered during the period of organogenesis.  If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to a fetus. <span class="Italics">[See Use in Specific Populations, Sec.<a href="#MN081"> 8.1</a>]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="MN060"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are described in greater detail in other sections of the label<span class="Italics">:</span></p>
<br><ul>
<li>Chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">Arachnoiditis</span> <span class="Italics">[see Warnings and Precautions (<a href="#MN051">5.1</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span> <span class="Italics">[see Warnings and Precautions (<a href="#MN052">5.2</a>)]</span>
</li>
<li>Transient elevations in CSF protein and CSF white blood cells <span class="Italics">[see Warnings and Precautions (<a href="#MN053">5.3</a>)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="MN061"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Most Frequently Reported Reactions</h2>
<p class="First">After intrathecal administration of cytarabine the most frequently reported reactions (≥ 10%) are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> NOS, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> NOS, <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait abnormal</span> NOS, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> NOS, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> NOS, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in limb</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> NOS, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> NOS, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> NOS, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> NOS, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">appetite decreased</span> NOS, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">neck stiffness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>,  <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> NOS.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="MN062"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.  The toxicity database consists of the observations made during Phase 1-4 studies.  The most common adverse reactions in all patients and in patients with <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> are shown in <a href="#table1">Table 1</a>.  The incidences of symptoms possibly reflecting <span class="product-label-link" type="condition" conceptid="441130" conceptname="Meningeal irritation">meningeal irritation</span> are shown in <a href="#table2">Table 2</a>.</p>
<a name="table1"></a><table class="Noautorules" width="900">
<caption><span>Table 1.   Incidence of adverse reactions occurring in &gt; 10% of patients in all Phase 1-4 adult study patients and in patients with lymphomatous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> receiving DepoCyt 50 mg or an active comparator </span></caption>
<col align="left" width="40%">
<col align="center" width="10%">
<col align="left" width="10%">
<col align="center" width="10%">
<col align="left" width="10%">
<col align="center" width="10%">
<col align="left" width="10%">
<tbody class="Headless">
<tr>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Botrule Toprule" align="center" colspan="4"><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></td>
</tr>
<tr>
<td class="Left" align="left" valign="bottom">System Organ Class / Preferred Term</td>
<td align="center" colspan="2" valign="bottom">All DepoCyt <br>(N=257)</td>
<td align="center" colspan="2" valign="bottom">DepoCyt<br>(N=33)</td>
<td align="center" colspan="2" valign="bottom">Ara-C<br>(N=28)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> NOS</td>
<td align="center">144</td>
<td align="left">(56%)</td>
<td align="center">17</td>
<td align="left">(52%)</td>
<td align="center">9</td>
<td align="left">(32%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">Arachnoiditis</span></td>
<td align="center">108</td>
<td align="left">(42%)</td>
<td align="center">14</td>
<td align="left">(42%)</td>
<td align="center">10</td>
<td align="left">(36%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td align="center">86</td>
<td align="left">(33%)</td>
<td align="center">12</td>
<td align="left">(36%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Gait abnormal</span> NOS</td>
<td align="center">60</td>
<td align="left">(23%)</td>
<td align="center">7</td>
<td align="left">(21 %)</td>
<td align="center">8</td>
<td align="left">(29%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> NOS</td>
<td align="center">52</td>
<td align="left">(20%)</td>
<td align="center">7</td>
<td align="left">(21%)</td>
<td align="center">1</td>
<td align="left">(4%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> NOS</td>
<td align="center">47</td>
<td align="left">(18%)</td>
<td align="center">7</td>
<td align="left">(21%)</td>
<td align="center">6</td>
<td align="left">(21%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">Memory impairment</span></td>
<td align="center">36</td>
<td align="left">(14%)</td>
<td align="center">4</td>
<td align="left">(12%)</td>
<td align="center">1</td>
<td align="left">(4%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span></td>
<td align="center">26</td>
<td align="left">(10%)</td>
<td align="center">4</td>
<td align="left">(12%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td align="center">22</td>
<td align="left">(9%)</td>
<td align="center">5</td>
<td align="left">(15%)</td>
<td align="center">5</td>
<td align="left">(18%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span> NOS</td>
<td align="center">9</td>
<td align="left">(4%)</td>
<td align="center">4</td>
<td align="left">(12%)</td>
<td align="center">1</td>
<td align="left">(4%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></td>
<td align="center">8</td>
<td align="left">(3%)</td>
<td align="center">0</td>
<td align="left">(0%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span> NOS</td>
<td align="center">7</td>
<td align="left">(3%)</td>
<td align="center">3</td>
<td align="left">(9%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">Peripheral sensory neuropathy</span></td>
<td align="center">7</td>
<td align="left">(3%)</td>
<td align="center">2</td>
<td align="left">(6%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td class="Botrule" align="left">   <span class="product-label-link" type="condition" conceptid="378256" conceptname="Abnormal reflex">Reflexes abnormal</span></td>
<td class="Botrule" align="center">7</td>
<td class="Botrule" align="left">(3%)</td>
<td class="Botrule" align="center">0</td>
<td class="Botrule" align="left">(0%)</td>
<td class="Botrule" align="center">3</td>
<td class="Botrule" align="left">(11%)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left">General Disorders and Administration Site<br> Conditions</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span></td>
<td align="center">103</td>
<td align="left">(40%)</td>
<td align="center">13</td>
<td align="left">(39%)</td>
<td align="center">15</td>
<td align="left">(54%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td align="center">81</td>
<td align="left">(32%)</td>
<td align="center">15</td>
<td align="left">(45%)</td>
<td align="center">12</td>
<td align="left">(43%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">64</td>
<td align="left">(25%)</td>
<td align="center">9</td>
<td align="left">(27%)</td>
<td align="center">13</td>
<td align="left">(46%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td align="center">41</td>
<td align="left">(16%)</td>
<td align="center">4</td>
<td align="left">(12%)</td>
<td align="center">4</td>
<td align="left">(14%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> NOS</td>
<td align="center">35</td>
<td align="left">(14%)</td>
<td align="center">9</td>
<td align="left">(27%)</td>
<td align="center">5</td>
<td align="left">(18%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> NOS</td>
<td align="center">35</td>
<td align="left">(14%)</td>
<td align="center">3</td>
<td align="left">(9%)</td>
<td align="center">5</td>
<td align="left">(18%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></td>
<td align="center">27</td>
<td align="left">(11 %)</td>
<td align="center">6</td>
<td align="left">(18%)</td>
<td align="center">7</td>
<td align="left">(25%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Fall</span></td>
<td align="center">12</td>
<td align="left">(5%)</td>
<td align="center">0</td>
<td align="left">(0%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">Mucosal inflammation</span> NOS</td>
<td align="center">8</td>
<td align="left">(3%)</td>
<td align="center">4</td>
<td align="left">(12%)</td>
<td align="center">2</td>
<td align="left">(7%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> NOS</td>
<td align="center">6</td>
<td align="left">(2%)</td>
<td align="center">1</td>
<td align="left">(3%)</td>
<td align="center">6</td>
<td align="left">(21%)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">117</td>
<td align="left">(46%)</td>
<td align="center">11</td>
<td align="left">(33%)</td>
<td align="center">15</td>
<td align="left">(54%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> NOS</td>
<td align="center">112</td>
<td align="left">(44%)</td>
<td align="center">11</td>
<td align="left">(33%)</td>
<td align="center">9</td>
<td align="left">(32%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">64</td>
<td align="left">(25%)</td>
<td align="center">8</td>
<td align="left">(24%)</td>
<td align="center">7</td>
<td align="left">(25%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> NOS</td>
<td align="center">31</td>
<td align="left">(12%)</td>
<td align="center">9</td>
<td align="left">(27%)</td>
<td align="center">9</td>
<td align="left">(32%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> NOS</td>
<td align="center">22</td>
<td align="left">(9%)</td>
<td align="center">5</td>
<td align="left">(15%)</td>
<td align="center">4</td>
<td align="left">(14%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></td>
<td align="center">20</td>
<td align="left">(8%)</td>
<td align="center">3</td>
<td align="left">(9%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">Hemorrhoids</span></td>
<td align="center">8</td>
<td align="left">(3%)</td>
<td align="center">0</td>
<td align="left">(0%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left">Musculoskeletal and Connective Tissue<br>Disorders</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td align="center">61</td>
<td align="left">(24%)</td>
<td align="center">7</td>
<td align="left">(21%)</td>
<td align="center">5</td>
<td align="left">(18%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in limb</span></td>
<td align="center">39</td>
<td align="left">(15%)</td>
<td align="center">4</td>
<td align="left">(12%)</td>
<td align="center">8</td>
<td align="left">(29%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">Neck pain</span></td>
<td align="center">36</td>
<td align="left">(14%)</td>
<td align="center">5</td>
<td align="left">(15%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center">29</td>
<td align="left">(11%)</td>
<td align="center">3</td>
<td align="left">(9%)</td>
<td align="center">4</td>
<td align="left">(14%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">Neck stiffness</span></td>
<td align="center">28</td>
<td align="left">(11%)</td>
<td align="center">2</td>
<td align="left">(6%)</td>
<td align="center">4</td>
<td align="left">(14%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span> NOS</td>
<td align="center">25</td>
<td align="left">(10%)</td>
<td align="center">5</td>
<td align="left">(15%)</td>
<td align="center">2</td>
<td align="left">(7%)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left">Psychiatric Disorders</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center">35</td>
<td align="left">(14%)</td>
<td align="center">6</td>
<td align="left">(18%)</td>
<td align="center">7</td>
<td align="left">(25%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></td>
<td align="center">26</td>
<td align="left">(10%)</td>
<td align="center">5</td>
<td align="left">(15%)</td>
<td align="center">2</td>
<td align="left">(7%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center">21</td>
<td align="left">(8%)</td>
<td align="center">6</td>
<td align="left">(18%)</td>
<td align="center">4</td>
<td align="left">(14%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="center">17</td>
<td align="left">(7%)</td>
<td align="center">1</td>
<td align="left">(3%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span> NOS</td>
<td align="center">35</td>
<td align="left">(14%)</td>
<td align="center">6</td>
<td align="left">(18%)</td>
<td align="center">5</td>
<td align="left">(18%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> NOS</td>
<td align="center">16</td>
<td align="left">(6%)</td>
<td align="center">2</td>
<td align="left">(6%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left">Metabolism and Nutrition Disorders</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></td>
<td align="center">33</td>
<td align="left">(13%)</td>
<td align="center">6</td>
<td align="left">(18%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Appetite decreased</span> NOS</td>
<td align="center">29</td>
<td align="left">(11%)</td>
<td align="center">4</td>
<td align="left">(12%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></td>
<td align="center">18</td>
<td align="left">(7%)</td>
<td align="center">4</td>
<td align="left">(12%)</td>
<td align="center">1</td>
<td align="left">(4%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td align="center">17</td>
<td align="left">(7%)</td>
<td align="center">5</td>
<td align="left">(15%)</td>
<td align="center">2</td>
<td align="left">(7%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></td>
<td align="center">15</td>
<td align="left">(6%)</td>
<td align="center">4</td>
<td align="left">(12%)</td>
<td align="center">2</td>
<td align="left">(7%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center">14</td>
<td align="left">(5%)</td>
<td align="center">1</td>
<td align="left">(3%)</td>
<td align="center">5</td>
<td align="left">(18%)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left">Investigations</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   Platelet count decreased</td>
<td align="center">8</td>
<td align="left">(3%)</td>
<td align="center">0</td>
<td align="left">(0%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left">Renal and Urinary Disorders</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">Incontinence</span> NOS</td>
<td align="center">19</td>
<td align="left">(7%)</td>
<td align="center">3</td>
<td align="left">(9%)</td>
<td align="center">5</td>
<td align="left">(18%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span></td>
<td align="center">14</td>
<td align="left">(5%)</td>
<td align="center">0</td>
<td align="left">(0%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left">Respiratory, Thoracic and Mediastinal<br>Disorders</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> NOS</td>
<td align="center">25</td>
<td align="left">(10%)</td>
<td align="center">4</td>
<td align="left">(12%)</td>
<td align="center">6</td>
<td align="left">(21%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td align="center">17</td>
<td align="left">(7%)</td>
<td align="center">3</td>
<td align="left">(9%)</td>
<td align="center">6</td>
<td align="left">(21%)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span></td>
<td align="center">29</td>
<td align="left">(11%)</td>
<td align="center">4</td>
<td align="left">(12%)</td>
<td align="center">4</td>
<td align="left">(14%)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left">Blood and Lymphatic Disorders</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> NOS</td>
<td align="center">31</td>
<td align="left">(12%)</td>
<td align="center">6</td>
<td align="left">(18%)</td>
<td align="center">5</td>
<td align="left">(18%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td align="center">27</td>
<td align="left">(11%)</td>
<td align="center">8</td>
<td align="left">(24%)</td>
<td align="center">9</td>
<td align="left">(32%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td align="center">26</td>
<td align="left">(10%)</td>
<td align="center">12</td>
<td align="left">(36%)</td>
<td align="center">7</td>
<td align="left">(25%)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left">Skin and Subcutaneous Tissue<br>Disorders</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Contusion</span></td>
<td align="center">6</td>
<td align="left">(2%)</td>
<td align="center">1</td>
<td align="left">(3%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> NOS</td>
<td align="center">6</td>
<td align="left">(2%)</td>
<td align="center">0</td>
<td align="left">(0%)</td>
<td align="center">4</td>
<td align="left">(14%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating increased</span></td>
<td align="center">6</td>
<td align="left">(2%)</td>
<td align="center">1</td>
<td align="left">(3%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> NOS</td>
<td align="center">21</td>
<td align="left">(8%)</td>
<td align="center">6</td>
<td align="left">(18%)</td>
<td align="center">2</td>
<td align="left">(7%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> NOS</td>
<td align="center">15</td>
<td align="left">(6%)</td>
<td align="center">5</td>
<td align="left">(15%)</td>
<td align="center">1</td>
<td align="left">(4%)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left">Ear and Labyrinth Disorders</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   Hypacusis</td>
<td align="center">15</td>
<td align="left">(6%)</td>
<td align="center">6</td>
<td align="left">(18%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> NOS</td>
<td align="center">22</td>
<td align="left">(9%)</td>
<td align="center">0</td>
<td align="left">(0%)</td>
<td align="center">5</td>
<td align="left">(18%)</td>
</tr>
<tr>
<td class="Bold Toprule" align="left">Neoplasms Benign, Malignant and<br>Unspecified (Incl <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">Cysts</span> and <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">Polyps</span>)</td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="left"></td>
</tr>
<tr>
<td class="Botrule" align="left">   Diffuse Large B-Cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> NOS</td>
<td class="Botrule" align="center">1</td>
<td class="Botrule" align="left">(0%)</td>
<td class="Botrule" align="center">1</td>
<td class="Botrule" align="left">(3%)</td>
<td class="Botrule" align="center">3</td>
<td class="Botrule" align="left">(11%)</td>
</tr>
</tbody>
</table>
<a name="table2"></a><table class="Noautorules" width="900">
<caption><span>Table 2.  Incidence of adverse reactions possibly reflecting <span class="product-label-link" type="condition" conceptid="441130" conceptname="Meningeal irritation">meningeal irritation</span> occurring in &gt; 10% of all studied adult patients receiving DepoCyt 50 mg or an active comparator*</span></caption>
<col align="left" width="40%">
<col align="center" width="10%">
<col align="left" width="10%">
<col align="center" width="10%">
<col align="left" width="10%">
<col align="center" width="10%">
<col align="left" width="10%">
<tfoot><tr><td class="Toprule" align="left" colspan="7">* <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">Hydrocephalus acquired</span>, CSF <span class="product-label-link" type="condition" conceptid="4240184" conceptname="Pleocytosis">pleocytosis</span> and <span class="product-label-link" type="condition" conceptid="4233749" conceptname="Meningism">meningism</span> occurred in ≤ 10% of all studied adult patients receiving<br> DepoCyt or an active comparator</td></tr></tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Left Toprule" align="left" valign="middle">System Organ Class / Preferred Term</td>
<td class="Botrule Toprule" align="center" colspan="2" valign="bottom">DepoCyt <br>(N=257)</td>
<td class="Botrule Toprule" align="center" colspan="2" valign="bottom">MTX<br>(N=78)</td>
<td class="Botrule Toprule" align="center" colspan="2" valign="bottom">Ara-C<br>(N=28)</td>
</tr>
<tr>
<td class="Bold Botrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></td>
<td class="Botrule Toprule" align="center"></td>
<td class="Botrule Toprule" align="left"></td>
<td class="Botrule Toprule" align="center"></td>
<td class="Botrule Toprule" align="left"></td>
<td class="Botrule Toprule" align="center"></td>
<td class="Botrule Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> NOS</td>
<td align="center">145</td>
<td align="left">(56%)</td>
<td align="center">33</td>
<td align="left">(42%)</td>
<td align="center">9</td>
<td align="left">(32%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">Arachnoiditis</span></td>
<td align="center">108</td>
<td align="left">(42%)</td>
<td align="center">15</td>
<td align="left">(19%)</td>
<td align="center">10</td>
<td align="left">(36%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> NOS</td>
<td align="center">56</td>
<td align="left">(22%)</td>
<td align="center">11</td>
<td align="left">(14%)</td>
<td align="center">1</td>
<td align="left">(4%)</td>
</tr>
<tr>
<td class="Bold Botrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></td>
<td class="Botrule Toprule" align="center"></td>
<td class="Botrule Toprule" align="left"></td>
<td class="Botrule Toprule" align="center"></td>
<td class="Botrule Toprule" align="left"></td>
<td class="Botrule Toprule" align="center"></td>
<td class="Botrule Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">117</td>
<td align="left">(46%)</td>
<td align="center">24</td>
<td align="left">(31%)</td>
<td align="center">15</td>
<td align="left">(54%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> NOS</td>
<td align="center">112</td>
<td align="left">(44%)</td>
<td align="center">22</td>
<td align="left">(28%)</td>
<td align="center">9</td>
<td align="left">(32%)</td>
</tr>
<tr>
<td class="Bold Botrule Toprule" align="left">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></td>
<td class="Botrule Toprule" align="center"></td>
<td class="Botrule Toprule" align="left"></td>
<td class="Botrule Toprule" align="center"></td>
<td class="Botrule Toprule" align="left"></td>
<td class="Botrule Toprule" align="center"></td>
<td class="Botrule Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td align="center">61</td>
<td align="left">(24%)</td>
<td align="center">15</td>
<td align="left">(19%)</td>
<td align="center">5</td>
<td align="left">(18%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">Neck pain</span></td>
<td align="center">36</td>
<td align="left">(14%)</td>
<td align="center">6</td>
<td align="left">(8%)</td>
<td align="center">3</td>
<td align="left">(11%)</td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">Neck stiffness</span></td>
<td align="center">28</td>
<td align="left">(11%)</td>
<td align="center">1</td>
<td align="left">(1%)</td>
<td align="center">4</td>
<td align="left">(14%)</td>
</tr>
<tr>
<td class="Bold Botrule Toprule" align="left">General Disorders and Administration<br>Site Conditions</td>
<td class="Botrule Toprule" align="center"></td>
<td class="Botrule Toprule" align="left"></td>
<td class="Botrule Toprule" align="center"></td>
<td class="Botrule Toprule" align="left"></td>
<td class="Botrule Toprule" align="center"></td>
<td class="Botrule Toprule" align="left"></td>
</tr>
<tr>
<td align="left">   <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td align="center">81</td>
<td align="left">(32%)</td>
<td align="center">15</td>
<td align="left">(19%)</td>
<td align="center">12</td>
<td align="left">(43%)</td>
</tr>
</tbody>
</table>
<p>During the clinical studies, 2 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> related to DepoCyt were reported.  One patient at the 125 mg dose level died of <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> 36 hours after receiving an intraventricular dose of DepoCyt.  This patient, however, was also receiving concomitant whole brain irradiation and had previously received intraventricular methotrexate.  The other patient received DepoCyt, 50 mg by the intraventricular route and developed <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">focal seizures</span> progressing to <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>.  This patient died approximately 8 weeks after the last dose of study medication.  In the controlled <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> study, the patient incidence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> was higher in the DepoCyt group (4/17, 23.5%) than in the cytarabine group (1/16, 6.3%).  The <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of 1 additional patient was considered “possibly? related to DepoCyt.  He was a 63-year-old with extensive <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> involving the nasopharynx, brain, and meninges with multiple neurologic deficits who died of apparent disease progression 4 days after his second dose of DepoCyt.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="MN070"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<p class="First">No formal assessments of pharmacokinetic drug-drug interactions between DepoCyt and other agents have been conducted.  Concomitant administration of DepoCyt with other antineoplastic agents administered by the intrathecal route has not been studied.  With intrathecal cytarabine and other cytotoxic agents administered intrathecally, enhanced <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> has been associated with coadministration of drugs.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="MN080"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="MN081"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy Category D</h2>
<p class="First"><span class="Italics">[see Warnings and Precautions (<a href="#MN054">5.4</a>)]</span></p>
<p class="Italics">Risk Summary</p>
<p>There are no studies assessing the reproductive toxicity of DepoCyt.  The systemic exposure of cytarabine following intrathecal administration of DepoCyt is negligible.  Cytarabine can cause fetal harm if a pregnant woman is exposed to the drug systemically.  Three anecdotal cases of major <span class="product-label-link" type="condition" conceptid="134741" conceptname="Congenital anomaly of limb">limb malformations</span> have been reported in infants after their mothers received intravenous cytarabine, alone or in combination with other agents, during the first trimester.   Advise women of childbearing potential to avoid becoming pregnant while receiving DepoCyt.  If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to a fetus.</p>
<p class="Italics">Animal Data</p>
<p>Cytarabine was teratogenic in mice (<span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, <span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">phocomelia</span>, deformed appendages, skeletal abnormalities) when doses ≥2 mg/kg/day were administered IP during the period of organogenesis (about 0.2 times the recommended human dose on a mg/m<span class="Sup">2</span> basis), and in rats (deformed appendages) when 20 mg/kg was administered as a single IP dose on day 12 of gestation (about 4 times the recommended human dose on a mg/m<span class="Sup">2</span> basis).  Single IP doses of 50 mg/kg in rats (about 10 times the recommended human dose on a mg/m<span class="Sup">2</span> basis) on day 14 of gestation reduced prenatal and postnatal brain size and permanent impairment of learning ability. </p>
<p>Cytarabine was embryotoxic in mice when administered during the period of organogenesis.  Embryotoxicity was characterized by decreased fetal weight at 0.5 mg/kg/day (about 0.05 times the recommended human dose on mg/m<span class="Sup">2</span> basis), and increased early and late resorptions and decreased live litter sizes at 8 mg/kg/day (approximately equal to the recommended human dose on mg/m<span class="Sup">2</span> basis).  </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="MN083"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether cytarabine is excreted in human milk following intrathecal DepoCyt administration.  The systemic exposure to free cytarabine following intrathecal treatment with DepoCyt was negligible.  Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="MN084"></a><a name="section-8.3"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">The safety and efficacy of DepoCyt in pediatric patients has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="MN086"></a><a name="section-8.4"></a><p></p>
<h2>8.6 Hepatic and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The effects of hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of DepoCyt have not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="MN100"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">No overdosages with DepoCyt<span class="Sup">®</span> (cytarabine liposome injection) have been reported.  An <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with DepoCyt may be associated with severe chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span> including <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>.  In an early uncontrolled study without dexamethasone prophylaxis, single doses up to 125 mg were administered.  
							There is no antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of intrathecal DepoCyt or unencapsulated cytarabine released from DepoCyt.  Exchange of CSF with isotonic saline has been carried out in a case of intrathecal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of free cytarabine, and such a procedure may be considered in the case of DepoCyt <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should be directed at maintaining vital functions.
						</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="MN110"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">DepoCyt<span class="Sup">®</span> (cytarabine liposome injection) is a sterile, injectable suspension of the antimetabolite cytarabine, for intrathecal administration.  The chemical name of cytarabine is 4-amino-1 -β-D-arabinofuranosyl-2(1H)-pyrimidinone, and is also known as cytosine arabinoside .  It has a molecular formula of C<span class="Sub">9</span>H<span class="Sub">13</span>N<span class="Sub">3</span>O<span class="Sub">5</span>, and a molecular weight 243.22 g/mol.  Cytarabine has the following structural formula:</p>
<p><img alt="Molecular structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d05d299-b9b0-4bf6-95cf-904dcc4e1f84&amp;name=depocyt-figure-1.jpg"></p>
<p>DepoCyt is available as a single-dose vial containing 50 mg/5 mL (10 mg/mL) of cytarabine.  DepoCyt is formulated as a sterile, non-pyrogenic, white to off-white suspension of cytarabine liposomes in 0.9% w/v sodium chloride in water for injection.  Each mL contains 10 mg cytarabine, 4.4 mg <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, 1.2 mg triolein, 5.7 mg dioleoylphosphatidylcholine (DOPC), and 1.0 mg dipalmitoylphosphatidylglycerol (DPPG).  DepoCyt is preservative-free.  The pH of the product <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> within the range from 5.5 to 8.5.</p>
<p>Liposome drug products may behave differently from nonliposome drug products. DepoCyt (cytarabine liposome injection) is not equivalent to, and cannot be substituted for, other drug products containing cytarabine.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="MN120"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="MN121"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">DepoCyt<span class="Sup">®</span> (cytarabine liposome injection) is a sustained-release formulation of the active ingredient cytarabine designed for direct administration into the cerebrospinal fluid (CSF).  Cytarabine is a cell cycle phase-specific antineoplastic agent, affecting cells only during the S-phase of cell division.  Intracellularly, cytarabine is converted into cytarabine-5-triphosphate (ara-CTP), which is the active metabolite.  The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition of DNA polymerase.  Incorporation into DNA and RNA may also contribute to cytarabine cytotoxicity.  Cytarabine is cytotoxic to proliferating mammalian cells in culture.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="MN123"></a><a name="section-11.2"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First">Following intrathecal administration of DepoCyt 50 mg, peak levels of free CSF cytarabine were observed within 1 hour of dosing and ranged from 30 to 50 mcg/mL.  The terminal half-life for the free CSF cytarabine ranged from of 5.9 to 82.4 hours.  Systemic exposure to cytarabine was negligible following intrathecal administration of DepoCyt 50 mg.</p>
<p class="Underline">Metabolism and Elimination</p>
<p>The primary route of elimination of cytarabine is metabolism to the inactive compound ara-U, followed by urinary excretion of ara-U.  In contrast to systemically administered cytarabine, which is rapidly metabolized to ara-U, conversion to ara-U in the CSF is negligible after intrathecal administration because of the significantly lower cytidine deaminase activity in the CNS tissues and CSF.  The CSF clearance rate of cytarabine is similar to the CSF bulk flow rate of 0.24 mL/min.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="MN130"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="MN131"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No carcinogenicity, mutagenicity or impairment of fertility studies have been conducted with DepoCyt.  </p>
<p>Cytarabine was mutagenic in <span class="Italics">in vitro</span> tests and was clastogenic <span class="Italics">in vitro</span> (chromosome aberrations and SCE in human leukocytes) and <span class="Italics">in vivo</span> (chromosome aberrations and SCE assay in rodent bone marrow, mouse micronucleus assay).  Cytarabine caused the transformation of hamster embryo cells and rat H43 cells in vitro.  </p>
<p>No studies assessing the impact of cytarabine on fertility are available in the literature.  Cytarabine was clastogenic to meiotic cells; a dose-dependent increase in sperm-head abnormalities and chromosomal aberrations occurred in mice given IP cytarabine. Because the systemic exposure to free cytarabine following intrathecal treatment with DepoCyt was negligible, the risk of impaired fertility after intrathecal DepoCyt is likely to be low.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="MN140"></a><a name="section-13"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<p class="First">DepoCyt® (cytarabine liposome injection) was studied in 2 controlled clinical studies that enrolled patients with <span class="product-label-link" type="condition" conceptid="4042194" conceptname="Malignant meningitis">neoplastic meningitis</span>. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="MN141"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Study 1 – <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">Solid Tumors</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span>, or <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span> </h2>
<p class="First">The first study, which was a randomized, multi-center, multi-arm study involving a total of 99 treated patients, compared 50 mg of DepoCyt administered every 2 weeks to standard intrathecal chemotherapy administered twice a week to patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, or <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>.  For patients with <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, standard therapy consisted of 50 mg of unencapsulated cytarabine given twice a week.  Thirty-three <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> patients (17 DepoCyt, 16 cytarabine) were treated.  Patients went off study if they had not achieved a complete response defined as clearing of the CSF from all previously positive sites in the absence of progression of neurological symptoms, after 4 weeks of treatment with study drug.</p>
<p>In the first study, complete response was prospectively defined as (1) conversion, confirmed by a blinded central pathologist, from a positive examination of the CSF for malignant cells to a negative examination on two separate occasions (at least 3 days apart, on day 29 and later) at all initially positive sites, together with (2) an absence of neurological progression during the treatment period.</p>
<p>The complete response rates in the first study of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> are shown in <a href="#table3">Table 3</a>.  Although there was a plan for central pathology review of the data, in 4 of the 7 responding patients on the DepoCyt arm this was not accomplished and these cases were considered to have had a complete response based on the reading of an unblinded pathologist.  The median overall survival of all treated patients was 99.5 days in the DepoCyt group and 63 days in the cytarabine group.  In both groups the majority of patients died from progressive systemic disease, not <span class="product-label-link" type="condition" conceptid="4042194" conceptname="Malignant meningitis">neoplastic meningitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="MN142"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Study 2 – <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></h2>
<p class="First">The second study was a randomized, multi-center, multi-arm study involving a total of 124 treated patients with either <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> or <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>.  In this study, 24 patients with <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> were randomized and treated with DepoCyt or cytarabine.  Patients received 6 two-week induction cycles of DepoCyt 50 mg every 2 weeks or cytarabine 50 mg twice weekly.  Patients then received four maintenance cycles of DepoCyt 50 mg every 4 weeks, or cytarabine 50 mg weekly for 4 weeks.  In both studies, patients received concurrent treatment with dexamethasone to minimize symptoms associated with chemical <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span> [<span class="Italics">see Warnings and Precautions (<a href="#MN050">5</a>) and Dosage and Administration (<a href="#MN020">2</a>)</span>].  In this study, cytological response was assessed in a blinded fashion utilizing a similar definition as in the first study.  The results in patients with lymphomatous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> are shown in <a href="#table3">Table 3</a>.</p>
<a name="table3"></a><table cellpadding="3" class="Noautorules" width="300">
<caption><span>Table 3: Complete Cytological Responses in Patients with Lymphomatous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span></span></caption>
<col align="center">
<col align="center">
<col align="center">
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center">DepoCyt<span class="Sup">®</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Cytarabine</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Study 1<br>95% CI</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7/17 (41%)<br>(18%, 67%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1/16 (6%)<br>(0%, 30%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Study 2<br>95% CI</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4/12 (33%)<br>(10%, 65%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2/12 (17%)<br>(2%, 48%)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="MN150"></a><a name="section-14"></a><p></p>
<h1>15  REFERENCES</h1>
<p class="First">OSHA Hazardous Drugs. OSHA. [Accessed on November 4, 2014, from http://www.osha.gov/SLTC/hazardousdrugs/index.html]. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="MN160"></a><a name="section-15"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">DepoCyt<span class="Sup">®</span> (cytarabine liposome injection) is supplied as a sterile, white to off-white suspension in 5 mL glass, single dose vials.</p>
<p>Store refrigerated at 2° to 8°C (36° to 46°F).  Protect from freezing and avoid aggressive <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>. </p>
<p>Available in individual carton containing one ready to use vial.  NDC 57665-331-01.</p>
<p>Do not use beyond expiration date printed on the label.</p>
<p>DepoCyt is a genotoxic drug.  Follow special handling and disposal procedures <span class="Italics">[see References (<a href="#MN150">15</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="MN170"></a><a name="section-16"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<ul>
<li>Advise patients of the following expected adverse events:   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and about the early signs and symptoms of <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>.  </li>
<li>Advise patients of the importance of concurrent dexamethasone administration should be emphasized at the initiation of each cycle of DepoCyt<span class="Sup">®</span> treatment. </li>
<li>Instruct patients to seek medical attention if signs or symptoms of <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> develop, or if oral dexamethasone is not well tolerated.</li>
</ul>
<p class="First">For additional information, contact Sigma-Tau Pharmaceuticals, Inc. at: 1-888-393-4584.</p>
<p>Manufactured by:<br>Pacira Pharmaceuticals, Inc., San Diego, CA 92121</p>
<p> </p>
<p>Distributed by: Sigma-Tau Pharmaceuticals, Inc., Gaithersburg, MD 20878</p>
<p> </p>
<p>U.S. patent Nos.</p>
<p>5,807,572<br>5,723,147<br>5,455,044<br>5,891,467</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="MN300"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - CARTON, 5mL VIAL</h1>
<p class="First">NDC 57665-331-01</p>
<p>1 Vial</p>
<p><span class="Bold">DepoCyt®</span></p>
<p>(cytarabine liposome injection)</p>
<p><span class="Bold">50 mg/5 mL</span></p>
<p>(10 mg/mL)</p>
<p>5mL STERILE</p>
<p>SINGLE-USE VIAL</p>
<p><span class="Bold">FOR INTRATHECAL USE ONLY</span></p>
<p>REFRIGERATE</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">sigma-tau</span></p>
<p><span class="Bold">Pharmaceuticals, Inc.</span></p>
<p>Manufactured by:</p>
<p><span class="Bold">Pacira Pharmaceuticals, Inc.</span></p>
<p>San Diego, CA 92121</p>
<p>Distributed by:</p>
<p><span class="Bold">Sigma-Tau</span></p>
<p><span class="Bold">Pharmaceuticals, Inc.,</span></p>
<p>Gaithersburg, MD 20878</p>
<p>U.S Patent Nos: 5,807,572; 5,723,147; 5,455,044; 5,891,467</p>
<p><span class="Bold">USUAL DOSAGE: See package insert for complete
									prescribing information.</span></p>
<p>DepoCyt® is a sterile, white to off-white suspension containing
								cytarabine encapsulated into multivesicular lipid-base particles, in
								Sodium Chloride 0.9% w/v in Water for Injection. Each 5 mL
								preservative-free vial contains 50 mg cytarabine at a concentration of
								10 mg/mL. The pH ranges from 5.5 to 8.5.</p>
<p>Professional assistance is available by calling toll-free
								866-792-5172.</p>
<p>Note - lipid encapsulation formulation - see package insert.</p>
<ul>
<li>FOR INTRATHECAL USE ONLY</li>
<li>Use with 4 hours of withdrawal from vial.</li>
<li>DO NOT FILTER.</li>
<li>PROTECT FROM FREEZING.</li>
<li>Refrigerate at 2° to 8°C (36° to 46°F).</li>
</ul>
<p><img alt="PDP" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9d05d299-b9b0-4bf6-95cf-904dcc4e1f84&amp;name=depocyt-figure-2.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEPOCYT 		
					</strong><br><span class="contentTableReg">cytarabine injection, lipid complex</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:57665-331</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRATHECAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CYTARABINE</strong> (CYTARABINE) </td>
<td class="formItem">CYTARABINE</td>
<td class="formItem">50 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">CHOLESTEROL</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIOLEIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>1,2-DIPALMITOYL-SN-GLYCERO-3-(PHOSPHO-RAC-(1-GLYCEROL))</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:57665-331-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021041</td>
<td class="formItem">10/22/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sigma-Tau Pharmaceuticals, Inc.
							(068301431)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sigma-Tau PharmaSource</td>
<td class="formItem"></td>
<td class="formItem">961822389</td>
<td class="formItem">LABEL(57665-331), PACK(57665-331)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pacira Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">783298615</td>
<td class="formItem">MANUFACTURE(57665-331), ANALYSIS(57665-331)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>71ffb8f6-7756-4392-9ab7-33db504af8a6</div>
<div>Set id: 9d05d299-b9b0-4bf6-95cf-904dcc4e1f84</div>
<div>Version: 8</div>
<div>Effective Time: 20150102</div>
</div>
</div> <div class="DistributorName">Sigma-Tau Pharmaceuticals, Inc.</div></p>
</body></html>
